Essential Pharma

News

Carlyle backs Essential refinancing and other funding news

Essential Pharma announces a €900m recapitalisation deal, while Noema Pharma, Angitia Biopharma, Citryll, and Veradermics also raise new cash.

News

Essential adds neuroblastoma drug with Renaissance buy

Essential Pharma has bought fellow UK drugmaker Renaissance Pharma, adding its first development-stage drug candidate, a therapy for hard-to-treat rare cancer neuroblastom

News

Chiesi signs $1.9bn deal to buy KalVista and its HAE drug

Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Using AI-driven synthetic personas to take your insights fur...

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.

Editor's Picks